Regional nodal irradiation after breast conserving surgery for HER2-positive breast cancer: Results of a sub analysis from the ALTTO trial.

Authors:

Abstract
604 Background: The optimal treatment of regional nodal areas following breast-conserving surgery (BCS) is a source of debate. Two randomized trials recently demonstrated that regional nodal irradiation (RNI) can reduce the risk of recurrence in early breast cancer; however,these trials were conducted in the pre-trastuzumab era.Whether these results are applicable to HER2-positive breast cancer patients treated with anti-HER2 targeted therapy, is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer, who were enrolled in the ALTTO phase III adjuvant trial and subjected to BCS. The primary objective of the present study was to examine the effect of RNI on disease-free survival (DFS). Secondary objectives included regional recurrences and overall survival (OS). A multivariate cox regression analysis adjusted for number of positive lymph nodes, tumor size, grade, age, hormone receptors status, presence of macrometastatis, treatment arm, and chemotherapy timing was carried out to interrogate the relation between RNI and DFS. Results: 1,664 HER2-positive breast cancer patients were included, of whom 878 patients (53%) had received RNI to the axillary, supraclavicular and/or internal mammary lymph nodes. Patients in the RNI group had higher nodal burden (55% vs 13% patients with ≥ 4 positive lymph nodes) and more frequently tumors larger than 2cm (53% vs 44%). At a median follow-up of 4.5 years, DFS was 84% in the RNI group and 88% in the non-RNI group. No differences in regional recurrence (1% vs 1%) and in OS (94% vs 95%) were observed between the two groups. In the multivariate analysis, there was no significant association between RNI and DFS (HR 0.96, 95% CI 0.71-1.29). Conclusions: Our analysis did not demonstrate a DFS benefit of RNI in HER2-positive, node positive patients treated with adjuvant HER2-targeted therapy. The benefit of RNI in HER2-positive breast cancer needs further testing within randomized clinical trials.